174 related articles for article (PubMed ID: 38167599)
21. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
22. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
23. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
24. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H
Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856
[TBL] [Abstract][Full Text] [Related]
25. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
26. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
28. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
29. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
[TBL] [Abstract][Full Text] [Related]
30. Germline control of somatic Kras mutations in mouse lung tumors.
Borrego A; Cabrera WHK; Jensen JR; Correa M; Ribeiro OG; Starobinas N; De Franco M; Pettinicchio A; Dragani TA; Ibañez OCM; Manenti G
Mol Carcinog; 2018 Jun; 57(6):745-751. PubMed ID: 29500885
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathogenesis of transplacentally induced mouse lung tumors.
Miller MS; Leone-Kabler S; Rollins LA; Wessner LL; Fan M; Schaeffer DO; McEntee MF; O'Sullivan MG
Exp Lung Res; 1998; 24(4):557-77. PubMed ID: 9659583
[TBL] [Abstract][Full Text] [Related]
32. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
33. The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers.
Fritz JM; Dwyer-Nield LD; Russell BM; Malkinson AM
J Thorac Oncol; 2010 Feb; 5(2):254-7. PubMed ID: 20101149
[TBL] [Abstract][Full Text] [Related]
34. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
[TBL] [Abstract][Full Text] [Related]
35. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
36. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
37. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
[TBL] [Abstract][Full Text] [Related]
38. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
[No Abstract] [Full Text] [Related]
39. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
40. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.
Marabese M; Caiola E; Garassino MC; Rastelli G; Settanni G; Brugnara S; Broggini M; Ganzinelli M
J Thorac Oncol; 2016 Jul; 11(7):1170-5. PubMed ID: 27058911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
